Revvity (NYSE:RVTY) Given New $124.00 Price Target at TD Cowen

Revvity (NYSE:RVTY) had its price target increased by research analysts at TD Cowen from $120.00 to $124.00 in a report issued on Tuesday, Marketbeat reports. The brokerage presently has a “buy” rating on the stock. TD Cowen’s price objective would suggest a potential upside of 15.31% from the company’s previous close.

Several other analysts have also weighed in on RVTY. The Goldman Sachs Group initiated coverage on Revvity in a research note on Tuesday, December 9th. They issued a “neutral” rating and a $105.00 price objective on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Revvity in a research report on Monday, December 29th. Bank of America downgraded Revvity from a “buy” rating to a “neutral” rating and set a $110.00 price objective on the stock. in a report on Monday, December 15th. Robert W. Baird increased their target price on Revvity from $122.00 to $123.00 and gave the company an “outperform” rating in a research report on Tuesday, October 28th. Finally, Guggenheim initiated coverage on Revvity in a research note on Wednesday, October 15th. They issued a “neutral” rating for the company. Six equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $112.75.

Revvity Price Performance

NYSE:RVTY traded up $0.45 during trading hours on Tuesday, reaching $107.54. 141,112 shares of the company were exchanged, compared to its average volume of 1,491,876. The business has a 50 day moving average of $104.09 and a 200 day moving average of $95.52. Revvity has a 1-year low of $81.36 and a 1-year high of $124.82. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.75 and a quick ratio of 1.44. The company has a market capitalization of $12.19 billion, a P/E ratio of 54.02, a P/E/G ratio of 3.32 and a beta of 1.06.

Revvity (NYSE:RVTY) last released its earnings results on Monday, February 2nd. The company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.55 by $0.15. Revvity had a return on equity of 7.52% and a net margin of 8.44%.The firm had revenue of $772.06 million during the quarter, compared to the consensus estimate of $759.81 million. During the same period in the prior year, the company posted $1.42 EPS. The company’s revenue was up 5.9% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.350-5.450 EPS. Research analysts forecast that Revvity will post 4.94 EPS for the current year.

Revvity announced that its board has approved a share buyback plan on Monday, October 27th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the company to purchase up to 8.7% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.

Institutional Trading of Revvity

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. EdgePoint Investment Group Inc. raised its position in shares of Revvity by 26.3% during the third quarter. EdgePoint Investment Group Inc. now owns 8,574,280 shares of the company’s stock valued at $751,536,000 after buying an additional 1,784,620 shares during the last quarter. Invesco Ltd. grew its stake in Revvity by 15.7% during the third quarter. Invesco Ltd. now owns 2,553,515 shares of the company’s stock valued at $223,816,000 after acquiring an additional 346,313 shares in the last quarter. UBS Group AG lifted its stake in Revvity by 22.3% in the 3rd quarter. UBS Group AG now owns 2,179,505 shares of the company’s stock worth $191,034,000 after purchasing an additional 397,160 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Revvity by 39.0% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,125,957 shares of the company’s stock valued at $186,307,000 after purchasing an additional 596,436 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in shares of Revvity by 127.0% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,751,612 shares of the company’s stock valued at $171,921,000 after purchasing an additional 980,142 shares in the last quarter. Institutional investors own 86.65% of the company’s stock.

More Revvity News

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Q4 earnings beat and revenue beat — Revvity reported adjusted EPS $1.70 and revenue $772.06M, topping estimates and showing solid year-over-year growth, a primary reason the stock is trading up. MarketBeat Q4 report
• Positive Sentiment: FY2026 guidance raised/slightly above Street — management set EPS guidance of $5.350–$5.450 and revenue around $3.0B, which exceeded consensus and supports a more bullish forward outlook. Reuters: forecasts above estimates
• Positive Sentiment: Analyst target moved up — Wells Fargo raised its price target to $110 while keeping an “equal weight” rating, signaling some analyst support for upside (albeit measured). Benzinga note
• Neutral Sentiment: Earnings coverage and call details available — multiple transcripts and call highlights provide additional color on segment performance and margin drivers; useful for modeling but not a new catalyst by itself. Yahoo Finance transcript
• Neutral Sentiment: Extended analysis and valuation discussions — third-party write-ups and DCF/valuation pieces are out assessing whether recent weakness creates a buying opportunity; these may influence longer-term sentiment but are not immediate catalysts. Yahoo UK valuation piece
• Negative Sentiment: Segment headwinds: academic research funding remains weak — Reuters and other reports note continued softness in academic/research spending, which could pressure parts of Revvity’s business despite diagnostics strength. This is a potential medium-term risk to growth. Reuters: academic funding weakness

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.